PHASE I STUDY OF THE COMBINATION OF CARFILZOMIB AND PANOBINOSTAT FOR PATIENTS WITH RELAPSED AND REFRACTORY MYELOMA: A MULTICENTER MMRC CLINICAL TRIAL

被引：0
|
作者：
Kaufman, J. [1 ]
Zimmerman, T. [2 ]
Jakubowiak, A. [2 ]
Rosenbaum, C. [2 ]
Lewis, C.
Harvey, D. [1 ]
Nooka, A.
Heffner, L. [1 ]
Lonial, Sagar [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P771
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [21] A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: Preliminary results. Multiple myeloma research consortium (MMRC) trial
    Jakubowiak, A.
    Richardson, P.
    Zimmerman, T.
    Alsina, M.
    Lonial, S.
    Kendall, T.
    Hideshima, T.
    Sportelli, P.
    Birch, R.
    Henderson, I. C.
    Giusti, K.
    Anderson, K.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 154 - 155
  • [22] A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Gonsalves, Wilson, I
    Neparidze, Natalia
    Allred, Jacob B.
    Kumar, Shaji K.
    Reid, Joel M.
    Shapiro, Geoffrey
    Costello, Brian A.
    Piekarz, Richard
    Baz, Rachid C.
    Devarakonda, Srinivas
    [J]. BLOOD, 2022, 140 : 7315 - 7316
  • [23] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [24] A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
    Bringhen, Sara
    Magarotto, Valeria
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Gilestro, Milena
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Stocchi, Raffaella
    Ribolla, Rossella
    Di Sano, Chiara
    Patriarca, Francesca
    Passera, Roberto
    De Paoli, Lorenzo
    Oliva, Stefania
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    [J]. BLOOD, 2016, 128 (22)
  • [25] A multiple myeloma research consortium (MMRC) Multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with Relapsed/Refractory multiple myeloma (MM): Updated results
    Jakubowiak, Andrzej
    Zimmerman, Todd
    Alsina, Melissa
    Richardson, Paul
    Kaufman, Jonathan
    Kendall, T.
    Brozo, C.
    McAllister, A.
    Leister, C.
    Hideshima, T.
    Sportelli, P.
    Gardner, L.
    Birch, R.
    Henderson, I. C.
    Giusti, K.
    Anderson, Kenneth
    [J]. BLOOD, 2007, 110 (11) : 354A - 354A
  • [26] Panobinostat and Lenalidomide Combination Phase I Trial in Myeloma
    Spencer, A.
    Lonial, S.
    Taylor, K.
    Jalaluddin, M.
    Hazell, K.
    Bourquelot, P. M.
    San Miguel, J.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S52 - S53
  • [27] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    [J]. BLOOD, 2012, 120 (21)
  • [28] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
  • [29] A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma
    Keller, Jesse
    Fiala, Mark A.
    Sekhar, Jeevan
    Ceriotti, Connie
    Allen, Melissa
    Abboud, Camille N.
    Stockerl-Goldstein, Keith E.
    Wildes, Tanya M.
    Tomasson, Michael H.
    Vij, Ravi
    [J]. BLOOD, 2014, 124 (21)
  • [30] Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
    Liu, Liping
    Zhao, Ningning
    Xu, Wenjun
    Sheng, Zhixin
    Wang, Lida
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
12345